uniQure Sees Unusually High Options Volume (NASDAQ:QURE)

uniQure N.V. (NASDAQ:QURE) was the recipient of some unusual options trading on Tuesday. Investors bought 35,694 call options on the company. This represents an increase of approximately 488% compared to the typical daily volume of 6,074 call options.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew Kapusta sold 21,082 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total value of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares in the company, valued at approximately $23,448,291.32. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.65% of the stock is currently owned by company insiders.

Institutional Trading of uniQure

Large investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its position in shares of uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC boosted its holdings in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after buying an additional 1,398,749 shares in the last quarter. Artia Global Partners LP grew its position in shares of uniQure by 55.4% during the 4th quarter. Artia Global Partners LP now owns 1,023,539 shares of the biotechnology company’s stock worth $24,493,000 after buying an additional 364,700 shares during the period. Siren L.L.C. bought a new stake in shares of uniQure in the 1st quarter valued at $16,350,000. Finally, SG Americas Securities LLC boosted its position in uniQure by 1,107.3% in the first quarter. SG Americas Securities LLC now owns 776,604 shares of the biotechnology company’s stock worth $12,697,000 after purchasing an additional 712,278 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Stock Down 37.3%

Shares of NASDAQ:QURE traded down $14.60 during midday trading on Tuesday, reaching $24.51. 29,594,048 shares of the company were exchanged, compared to its average volume of 2,424,308. The firm has a market cap of $1.70 billion, a PE ratio of -6.11 and a beta of 0.94. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The stock has a fifty day simple moving average of $44.57 and a two-hundred day simple moving average of $33.25. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter last year, the firm earned ($0.69) earnings per share. As a group, sell-side analysts forecast that uniQure will post -3.82 earnings per share for the current year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported that AMT-130 slowed disease progression by 44% on the cUHDRS measure and 61% on Total Functional Capacity (TFC) at 48 months in high-dose patients. The company also highlighted 80% cUHDRS and 67% TFC slowing at 36 months among 15 high-dose patients. uniQure Announces Additional AMT-130 Data
• Positive Sentiment: The company said the FDA previously accepted the 36-month data as the basis for its submitted Biologics License Application under the accelerated approval pathway. uniQure also reported a dose-dependent treatment effect and generally manageable safety findings, supporting its view that AMT-130 remains on a potential path toward approval. UniQure Insists Huntington’s Drug Is Still on Track
• Neutral Sentiment: uniQure’s four-year results were based on small patient groups and comparisons with external natural-history controls. The company said missing data and survivor bias may have understated the treatment effect, while a post-hoc analysis using an older control dataset produced stronger results. These methodological issues leave investors assessing how regulators will view the evidence.
• Negative Sentiment: The key cUHDRS endpoint at 48 months showed 44% slowing but was not statistically significant (p=0.144), undermining confidence in the durability and reliability of AMT-130’s benefit. News coverage characterized the results as a clinical-trial miss, prompting a heavy selloff and likely increasing concerns about whether the FDA will accept the data for accelerated approval. Reuters Trial Results Report
• Negative Sentiment: Two investor law firms announced securities investigations and invited QURE shareholders to participate, adding legal and reputational pressure following the data disclosure. SBS Law Fraud Investigation Announcement

Analyst Ratings Changes

Several research analysts recently commented on the company. Wolfe Research upgraded uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research note on Wednesday, July 29th. Wells Fargo & Company upped their target price on uniQure from $60.00 to $75.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a research note on Wednesday, June 17th. HC Wainwright reiterated a “buy” rating on shares of uniQure in a research report on Tuesday. Finally, The Goldman Sachs Group increased their target price on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $59.55.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure’s pipeline has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease.